# A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

> **NCT01610336** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 161 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** INC280
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01610336
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-05
- **Primary completion:** 2016-06-10
- **Final completion:** 2020-05-27
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610336, "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01610336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*